Difference between revisions of "Part:BBa K3496006"

Revision as of 16:26, 26 October 2020

Eriodictyol producing composite part

Eriodictyol producing composite part This is a composite part，a collection of BBa_K1033001 (4CL), BBa_K1497001 (CHS), BBa_K1497000 (CHI), BBa_K3496005 (F3‘H), aiming to biosynthesis Eriodictyol in Saccharomyces cerevisiae and improve the existing part BBa_K1497017. BBa_K1497017 is another composite part Naringenin producing operon under the T7 promoter. Firstly, in terms of final product, compared with Naringenin, Eriodictyol has one more hydroxyl group on the B ring and higher anti-oxidation activity and higher Medicinal Value for health care. Secondly, since in the last step of eriodictyol metabolic pathway when P450 enzyme F3‘H hydroxylated naringenin to obtain the final product eriodictyol, it is supposed to happen in eukaryotic organisms instead of a prokaryotic cell which is unable to provide the membrane structure required for post-modification of the enzyme. As the biological chassis, Saccharomyces cerevisiae meets the need. Thirdly, when we look at the entire pathway throughout，this improved part is coordinating with enzyme TAL in E. coli which addresses the separation of metabolic pathways. The sharing of the burden of gene expression as well as the cross-feeding of metabolites, together improve metabolic efficiency and robustness to achieve high‐efficiency bioproduction of the final product. ‘

Sequence and Features